Oncology Deal Benchmarks
Licensing deals, acquisitions, and collaborations in solid tumors and hematologic malignancies. Benchmarks derived from 969 verified transactions.
969
Total Deals
$839M
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
212
license
199
acquisition
206
collaboration
183
option
158
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Arvinas and Pfizer → Rigel Pharmaceuticals VEPPANU (vepdegestrant) | license | $70M | $405M | May 2026 |
Hengrui Pharmaceuticals → Bristol-Myers Squibb Multi-asset collaboration (13 programs) | collaboration | $600M | $15.2B | May 2026 |
QIMR Berghofer → Kazia Therapeutics MSETC | license | $1M | — | Apr 2026 |
Telix Pharmaceuticals Limited → Regeneron Pharmaceuticals, Inc. | collaboration | $40M | $2.1B | Apr 2026 |
Tubulis → Gilead Sciences TUB-040 | acquisition | $3.1B | $5.0B | Apr 2026 |
Insilico Medicine → Eli Lilly AI-developed oral therapeutics (multiple preclinical programs) | license | $115M | $2.8B | Mar 2026 |
Synnovation Therapeutics → Novartis SNV4818 | acquisition | $2.0B | $3.0B | Mar 2026 |
Pikavation Therapeutics → Novartis SNV4818 | acquisition | $2.0B | $3.0B | Mar 2026 |
CytomX Therapeutics → Astellas Pharma | collaboration | $80M | $1.7B | Mar 2026 |
Vir Biotechnology → Astellas VIR-5500 | collaboration | $335M | $1.7B | Mar 2026 |
Benchmark Your Oncology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 969 verified oncology transactions.
Run Oncology Benchmark